Kotra Industries BhdXKLS:0002 84 ROE % is 11.36% as of Mar. 2026, which is 21% below its 10-year median of 14.47. GuruFocus rates XKLS:0002 with a GF Score™ of 84/100 and a GF Value™ of RM4.33 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 936 Drug Manufacturers companies, Kotra Industries Bhd ranks better than 75.11% on this metric.
The historical rank and industry rank for Kotra Industries Bhd's ROE % or its related term are showing as below:
XKLS:0002'
s ROE % Range Over the Past 10 Years
Min: 6.14 Med: 14.47 Max: 27.56
Current: 13.51
During the past 13 years, Kotra Industries Bhd's highest ROE % was 27.56%. The lowest was 6.14%. And the median was 14.47%.
XKLS:0002's ROE % is ranked better than 75.11% of 936
companies
in the Drug Manufacturers industry
Industry Median: 5.865
vs XKLS:0002: 13.51
Kotra Industries Bhd (XKLS:0002) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kotra Industries Bhd's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kotra Industries Bhd ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kotra Industries Bhd's ROE % distribution charts can be found below:
* The bar in red indicates where Kotra Industries Bhd's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Kotra Industries Bhd (XKLS:0002) has a ROE % of 11.36% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Kotra Industries Bhd and its competitors. This is 21% below median its historical median of 14.47. Over the past decade, Kotra Industries Bhd's ROE % has ranged from 6.14 to 27.56. According to the industry distribution chart, Kotra Industries Bhd ranks #233 out of 936 companies in the Drug Manufacturers industry, placing it in the top 24.9%.
Is Kotra Industries Bhd's ROE % too high?
Kotra Industries Bhd's current ROE % of 11.36% is 21% below median its 10-year median of 14.47. Over the past 10 years, this metric has ranged from a low of 6.14 to a high of 27.56. The Drug Manufacturers industry median ROE % is 5.87. Kotra Industries Bhd's value of 11.36% is 93.7% above this industry median. Based on the distribution chart, Kotra Industries Bhd ranks #233 out of 936 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kotra Industries Bhd has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kotra Industries Bhd's ROE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kotra Industries Bhd ranks #233 out of 936 companies for ROE %. This places Kotra Industries Bhd in the top 25% of its industry — outperforming the majority of peers. The industry median ROE % is 5.87. Kotra Industries Bhd's value of 11.36% is 93.7% above this benchmark. Historically, Kotra Industries Bhd's own ROE % has ranged from 6.14 to 27.56 over the past decade. While the company's 10-year median is 14.47 vs. the industry median of 5.87, Kotra Industries Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.87, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kotra Industries Bhd's current ROE % of 11.36% is 93.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Kotra Industries Bhd and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kotra Industries Bhd's current ROE % is 11.36%, which is 21% below median its own 10-year median of 14.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kotra Industries Bhd stock overvalued right now?
Based on GuruFocus' analysis, Kotra Industries Bhd (XKLS:0002) is currently considered Modestly Undervalued. The stock's GF Value™ is RM4.33, compared to a current price of RM3.71 — trading 14.3% below its estimated fair value. The current ROE % is 11.36%, which is 21% below median its 10-year median of 14.47 and 93.7% above the Drug Manufacturers industry median of 5.87. Kotra Industries Bhd's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Kotra Industries Bhd (XKLS:0002), the current ROE % is 11.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kotra Industries Bhd (XKLS:0002) Overvalued in 2026?
Based on GuruFocus' analysis, Kotra Industries Bhd stock appears to be undervalued.
The current stock price of RM3.71 is trading 14.3% below its estimated GF Value™ of RM4.33.
GuruFocus considers Kotra Industries Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:0002:
ROE %: 11.36% (21% below median its 10-year median of 14.47)
GF Value™: RM4.33 vs. price of RM3.71 (14.3% below fair value)
Industry Position: 93.7% above the Drug Manufacturers median (#233 of 936)
No single metric tells the full story. See the XKLS:0002 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kotra Industries Bhd is a Malaysian pharmaceutical company engaged in the development, manufacturing, and supply of pharmaceutical and healthcare products supporting all life stages. Its portfolio includes life-saving medicines, OTC supplements, and nutrition products. The Group markets three core brands: Appeton, offering health supplements and nutrition across all age groups; Vaxcel, providing injectable medicines for infectious diseases, kidney care, and gastroenterology; and Axcel, specializing in oral and topical medicines for paediatrics, dermatology, and infectious diseases. The company operates in Malaysia and overseas, with the majority of revenue derived from Malaysia.
84GF Score
Get the complete analysis for XKLS:0002
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0002 has been successfully added to your 
